Brief

Following FDA Clearance, BioSight to Launch Clinical Trial for Treatment of Leukemia

The company’s compound will be administered to patients unfit for standard chemotherapy

Israel-based BioSight Ltd. has received clearance from the U.S. Food and Drug Administration and from the Israeli Ministry of Health to launch a phase 2b clinical trial for the treatment of acute myeloid leukemia (AML), a type of cancer that affects bone marrow and blood cells. The company intends to launch the trial in the upcoming month in 25 centers in both the U.S. and Israel, for newly-diagnosed participants that are unfit for standard chemotherapy.

 

Medical (illustration). Photo: Shutterstock